A
AaΦ23-like phage, 133, 134–135
ABC transporters, 19, 414–415
Abscesses, periodontal, 255, 355–356, 359–360, 395–396
Acid tolerance, 52, 109–114, 250
Acid-base cycling in oral cavity, and pathology, 108–109, 114, 124
Acid-base physiology of oral bacteria, 108–115
  acid tolerance, 52, 109–114, 250
  alkali production and tolerance, 109–110, 114–115
  and cariogenesis, 108–109, 111
Acid-fast staining, 5
Acquired (adaptive) immunity. *See* Immune system, adaptive immunity
Acquired immunodeficiency syndrome (AIDS), 319, 321–322, 430–431
Actinobacillus actinomycetemcomitans
  AaΦ23-like phage in, 133, 134–135
  aggressive periodontitis and, 193, 198–199, 255
  colony morphology variations in, 272
  epithelial internalization of, 104, 271–272
  JP2 clone, 193, 198–199
  natural transformation in, 132
  in periodontitis, 224–225, 259–260
  plasmids for research in, 157, 158
  population genetics of, 191, 193, 198–199
  strain variations in virulence, 194
  virulence traits of, 259–260, 268–273, 283
Actinomyces naeslundii, 224
Actinomyces spp.
  in cariogenesis, 233, 252
  in pulpal infections, 356
Acute-phase proteins, 27
Acyclovir, 329, 330
Adaptive immunity. *See* Immune system, adaptive immunity
Adhesins, 20, 55, 92–93, 95–96
Adhesion
  of *Actinobacillus actinomycetemcomitans*, 270–271
  bacterial surface structure and molecular promoters of, 91–94
  of *Eikenella corrodens*, 276
  to epithelial cells, 51, 96, 104, 275, 278
  of *Fusobacterium nucleatum*, 277
  host-specific constraints on, 51–53, 90, 91, 96, 101–104
  mechanisms of, 94–96
  and metabolic processes, 96–98
  pellicle and, 51, 53–55, 68–69
  in plaque formation, 20–21
  of *Porphyromonas gingivalis*, 264–265
  of *Prevotella intermedia*, 278
  of *Streptococcus mutans*, 247–250
  of *Tannerella forsythia*, 279
  of *Treponema denticola*, 274–275
Adhesion receptors, pellicle, 51, 55, 68–69
Aerobic bacteria, 18
Aerosol transmission, 426–427
Agarose gel electrophoresis, 77
Age of host, and oral bacterial colonization, 53, 90. *See also* Children, oral microbial colonization in
Agglutinins, in saliva, 66–68, 210
Aggressive periodontitis. *See* Generalized aggressive periodontitis; Localized aggressive periodontitis (LAP)
AIDS (acquired immunodeficiency syndrome), 319, 321–322, 430–431
Airborne routes of infection, 426–427
Alcohol consumption, antibiotic interactions and, 404
Alkali production, 109–110, 114–115
Allelic exchange mutagenesis, 176, 177
Alpha interferon, 330–331
Alveolar abscesses, 255, 355–356, 359–360, 395–396
Ameloblasts, 238
Amelogenin, 238
Amino acid metabolism by bacteria, in periodontal pockets, 109–110, 114–115
Aminoglycoside antibiotics, 387
Ammonia production, 109–110, 114–115, 250
Amphotericin B, 345
Ampicillin resistance, 408
Amplicon, 141
Amylase, salivary
  binding to streptococci, 70–71, 93–94
  function of, 65
Anaerobic bacteria
  characteristics of, 18–19
  culture of, 84–86
  oxidative metabolism and, 118–119
  in plaque of periodontitis, 57–58
Anaerobic culture chamber, 86
Angular cheilitis, 342, 343–344
Animal model studies
  of cariogenesis, 220–221, 239–242
  of periodontal disease, 286–289
Antibiotic resistance, 405–421. *See also specific antibiotics and antibiotic classes*
  biofilms and, 62, 122–123, 400–401
  efflux pumps and, 414–416, 420
  integrons in, 411–412, 418–419
  measurement of, 392–393
  mechanisms of, 407–408, 419–421
  mutations and, 412–414
  in nosocomial infections, 424
  in oral bacteria, 401, 416–418
  plasmids in, 135, 136, 405–407, 409, 410–411, 418–419
  transposons in, 138, 408–410, 418–419
Antibiotic sensitivity testing, 87–88
Antibiotics, 379–405. *See also specific antibiotics and antibiotic classes*
  antimetabolite antibiotics, 380, 390–391
  antimicrobial resistance to. *See* Antibiotic resistance
  cell wall synthesis inhibitors, 380–385
  classification of, 379–380
  in combination treatment, 391–392
  in dental practice, 393–405
  development of, 421–422
  drug interactions and, 402–405
  in endodontic therapy, 358
  nucleic acid synthesis inhibitors, 380, 388–389
  for odontogenic infections, 358, 392–400
    abscesses and cellulitis, 395–396
    periapical infections, 394–395
    pericoronitis, 400
    selection of, 396–400
  for periodontitis, 394, 400–403
  potency of, 392–393
  prophylactic use of, 394, 402, 403
  protein synthesis inhibitors, 380, 385–388

Antibiotics *(cont.)*
subgingival delivery systems for, 401–402
for tuberculosis, 391
Antibodies, 31–37, 44. *See also* Immunoglobulins
affinity and avidity of, 34
B lymphocytes in production of, 29, 42–43
classes of, 34, 35
cross-reacting, streptococcal, 221–222, 245–246
differential properties of, 34–35
in gingival crevicular fluid, 218
helper T cells in production of, 42–43
in localized aggressive periodontitis, 255, 285
mechanisms of protection by, 35–37
in mucosal defenses, 35–36
in periodontitis, 255, 282, 285, 293
in saliva. *See* Secretory immunoglobulin A
structure and specificity of, 31–34
Antibody-dependent cytotoxicity, 37
Anticoagulants, antibiotic interactions with, 404
Antifungal therapy, 338–340, 348
Antigen I/II (SpaP), 244–245
Antigen-antibody complexes, 34, 287
Antigenic determinant (epitope), 33, 34
Antigen-presenting cells, 323–324
Antigens
lymphocyte recognition of, 37–39
T lymphocyte processing of, 38–40
in vivo induced antigen assay for, 180–182
Antimetabolite antibiotics, 380, 390–391
Antimicrobial agents. *See also* Antibiotics
biofilm physiochemical gradients, and resistance to, 122–123
in endodontic therapy, 358–359
types of, 379
Antiretroviral therapy, 329–330
Antiviral compounds and therapies, 329–331, 332
Aphthous lesion, 309
Apoptosis, 43–44
Arbitrary primer PCR, in bacterial strain typing, 196
Archaea, 4, 7
Arginine, in ammonia production, 114–115
Arthus-type reactions, in periodontitis, 287
Aspergillosis, 345–346
Aspergillus fumigatus, 337
Atherosclerotic plaques, 266, 359, 373–375
ATP-binding cassette (ABC) transporters, 19, 414–415
Attenuated vaccines, 327–328
Australia antigen, 314
Autoimmunity, streptococcal systemic infection and, 371–372
Autoinducers, 99–100

B

B lymphocytes
antibody production by, 29, 42–43
antigen recognition by, 37, 38
mucosal, 217
in response to viruses, 323–324
T cell interactions, 42–43
Bacteremia
antibiotic prophylaxis for, 394, 402, 403
causes of, 108
Porphyromonas gingivalis and, 266, 373–375
systemic consequences of, 359, 361, 368
Bacteria. *See also* Oral microbiota; *names of specific organisms*
acid tolerance in, 52, 109–114, 250
adaptations of, to oral environment, 107–108
adhesion of. *See* Adhesion
agglutination of, 36, 66–68
alkali production and tolerance of, 109–110, 114–115
antibiotic resistance in. *See* Antibiotic resistance
in cariogenesis. *See* Cariogenic bacteria
classification of. *See* Classification of bacteria
coaggregation of. *See* Coaggregation
colonization by, 53, 90–91. *See also* Adhesion
genetic organization of, 15–17
genome sequences of, 15, 74–75, 81–83, 126–127
growth phases of, 17–20
identification of. *See* Identification of bacteria
immobilization of, by antibodies, 36
interactions of/communication between, 20–22, 99–101, 123
isolation of, from clinical samples, 76–77
metabolism of, and adhesion, 96–98
microscopy of, 84
mucosal interactions of. *See under* Epithelium, mucosal
naming of, 83
nutrition of
coaggregation and, 96–98
plaque nutrient levels and, 121, 123
saliva as source of, 70–71
transport proteins in, 19
oral cavity clearance of, 66–68
oral cavity organisms. *See* Oral microbiota
oxidative damage, 18, 52, 117–121
oxidative damage in. *See* Oxidative damage
oxygen metabolism in, 18–19, 117–120
in periodontal diseases, 255–258. *See also* Periodontal pathogens; *specific organisms*
physiology of. *See* Microbial physiology
in plaque formation. *See* Biofilms; Plaque
population genetics of. *See* Population genetics
in pulpal infections, 351, 353–356, 359–360
saliva interactions of, 65–71
sampling techniques for, 75–76
staining of, 5
structural components and products of
capsule, 12–13
cell wall peptidoglycan, 10
cytoplasmic membrane, 7–9
endospores, 14
fibrillar layer, 13
fimbriae/pili, 13, 92
flagella, 13–14
lipopolysaccharide, 9–10
lipoteichoic acid, 10–12
s-layer, 14
vesicles, 14
surface structural components of, and adhesion, 91–94
typing of strains of, 195–197
Bacterial clearance in oral cavity, 66–68
Bacterial endocarditis. *See* Endocarditis, infective
Bacteriocins, 21–22, 101
Bacteriophages
characteristics of, 16
in horizontal genetic transfer, 129
of oral bacteria, 133–135
virulent vs. temperate, 132–133, 134

Bacteroides forsythus. See *Tannerella forsythia*
Bead beating, DNA recovery technique, 76–77
Behçet's disease, 371, 372
β-Lactam antibiotics, 383–384, 396, 418, 419–420
β-Lactamase, 407, 418, 419–420
β-Lactamase inhibitor antibiotics, 385
Biofilms. *See also* Plaque
  antibiotic resistance and, 62, 122, 400–401
  bacterial interactions in, and pathogenicity, 21–22
  community composition of, 20–22
  defined, 20
  in dental water lines, 433–435
  formation of, 63
  physiological gradients in, 121–123
  structure and biology of, 61–62
Biohazardous waste disposal, 440, 443, 445
Births, preterm, 375
BLAST search engine, 74, 183
Blastomycosis, 346–347
Bone resorption/destruction
  Actinobacillus actinomycetemcomitans and, 273
  cytokine IL-1 in, 287
  immune factors in, 285–286
  mouse studies of, 288
  Porphyromonas gingivalis and, 267–268

C

Calcium hydroxide, 359
Calculus, formation of, 58–61
Calprotectin, 206
Candida albicans, 340–341. *See also* Candidiasis
  overgrowth of, 208
  prevalence of, in oral cavity, 333, 336
  replication of, 335
  and stomatitis, in AIDS, 321
  virulence factors of, 337
Candida spp., drug resistance in, 340
Candidiasis, 341–345
  clinical conditions, 341–344
  predisposing factors, 336, 341
  treatment of, 344–345
Capnocytophaga spp., 279
Capnophilic bacteria, 19, 84
Capsid, 297
Capsules, 12–13, 264
Carbapenem antibiotics, 383, 384
Carbohydrate ingestion
  and cariogenesis, 202, 234, 235, 241
  and pH changes, 114, 235
Cardiovascular disease, 266, 359, 372–375
Caries, 233–252. *See also* Cariogenesis; Cariogenic bacteria
  bacterial etiology of, 233, 237, 252
  genomic research in, 251–252
  immunization against, 220–224, 242–243, 244–247
  incidences of in populations, 235–236
  locations of, 237–239
  models for study of, 220–221, 239–242
  molecular techniques in study of, 247–252
  and pulpal infections, 351–352
Caries scoring, 241
Cariogenesis
  alkali production and, 114
  carbohydrate ingestion and, 202, 234, 235, 241
Cariogenesis *(cont.)*
  immunology of, 242–244
  oral pH and, 51–52, 108–109, 111, 235
Cariogenic bacteria. See also *Actinomyces* spp.; *Lactobacillus* spp.; *Streptococcus mutans*; *Streptococcus sobrinus*
  acid tolerance in, 111–112
  and biofilm composition, 21
  glucan and fructan production by, 12–13, 247–250
  serotypes and subgroups of, 237
  species involved, 233, 252
Caspofungin, 340, 345
Catabolite repression, 132
CD4 cells, 42, 217, 319–321, 323
CD8 cells, 42, 217, 323
cDNA microarrays, 251–252
Cell wall
  of bacteria, 10
  of fungi, 334, 340
Cell wall synthesis, as antibiotic target, 380–385
Cell-mediated immunity
  antibody interactions and, 37
  innate, 23–24
  T lymphocytes in, 43
Cellulitis, treatment of, 395–396
Cementum, 50, 238
Cephalosporin antibiotics, 383, 384, 396, 399
CGF. *See* Gingival crevicular fluid
Checkerboard analysis, 80–81
Cheilitis, candidiasis-associated, 342, 343–344
Chemotaxis disruption, by *Actinobacillus actinomycetemcomitans*, 272–273
Chemotaxis, in virulence of *Treponema denticola*, 274
Chicken pox, 311
Children, oral microbial colonization in, 90, 91, 193, 256, 257
Chloramphenicol, 387
Chlorhexidine, 223–224
Chromogranin, 211
Chromosomal integration of cloned DNA, 160–161
Chromosomes, bacterial, 15–16
Chymotrypsinlike proteinase complex. *See* Dentilisin
Ciprofloxacin, 397
Cistron, defined, 126
Clarithromycin, 397
Classification of bacteria. *See also* Molecular analysis techniques
  culture-based techniques for, 73, 87
  name assignment in, 83
  population genetics and, 187–189, 196–197
  ribosomal 16S DNA and, 74–75, 83
  schemes for, 4–6
Clindamycin, 387–388, 396–397, 401
Clinical samples, collection of, 75–76
Clonal population structure, 187–188
Cloning
  DNA, 169–172
  ribosomal 16S, 74–75, 81–83
Clotrimazole, 345
CMV (cytomegalovirus), 312, 325
Coaggregation
  and adhesion, 92–94
  of *Fusobacterium nucleatum*, 277
  mutual benefits of, 96–98
  of *Porphyromonas gingivalis*, 264–265

Coaggregation *(cont.)*
of *Prevotella intermedia*, 278
of *Tannerella forsythia*, 279
of *Treponema denticola*, 275
Colitis, antibiotic-associated, 404–405
Colonization/adhesion of bacteria. *See also* Adhesion
in children, 90, 91, 193, 256, 257
host factors in, 51–53, 90, 91, 96
Colony phase variation, in *Actinobacillus actinomycetemcomitans*, 272
Commensal oral microbiota
in host defenses, 208, 214
immune regulation of, 218–219
population genetics of, 191–192, 200
potential systemic pathogenicity of, 362–366
transmission of, 191–192
Competence
defined, 129
in gram-negative bacteria, 132
in streptococci, 100, 130, 131, 132, 166
Competence-stimulating peptide, 100–101
Complement system, 24, 26–27, 37
Complementation, 139, 145–146
Condyloma, 313
Conjugation, 17, 129–130, 135–138
Contact routes of infection, 428
Contraceptives, oral, antibiotic interactions with, 404
Coronary artery disease, 266, 359, 373–375
Coumarin antibiotics, 389
Cowpox vaccine, 326–327
C-reactive protein, 372–373
Creutzfeldt-Jakob disease, 431–433
Crevicular fluid. *See* Gingival crevicular fluid
Cross-infection. *See also* Infection control
defined, 423
dental water lines and, 433–435
emerging infectious diseases and, 430–433
routes of infection spread and, 427–430
sources of, 426–427
Cross-reacting antibodies, streptococcal, 221–222, 245–246
Cryptococcosis, 346
Cryptococcus neoformans, 334, 337
Culture mediums, 86–87, 338
Culturing
endodontic therapy and, 356–357
of fungi, 338–339
of oral bacteria, 73, 84–88
Cystatins, 210–211
Cytochrome P-450 system, in drug interactions, 402–404
Cytokines
functions of, 27
genetic variability in, 290–291
induction of acute-phase proteins by, 27
induction of, by *Eikenella corrodens*, 276
in mucosal defenses, 367
in periodontitis, 5, 225, 284–285, 287, 293
Cytolethal distending toxin/immunosuppressive factor, 268–269, 293
Cytomegalovirus (CMV), 312, 325
Cytoplasmic membrane, 7–9, 19
Cytoplasmic pH, relative to environmental pH, 111
Cytotoxic T cells, 29, 43, 323–324
Cytotoxicity
of *Actinobacillus actinomycetemcomitans*, 268–269, 293
antibody-dependent, 37
cell-mediated, 43–44
of *Fusobacterium nucleatum*, 277

D

Defensins, 205–206
Dendritic cells, 39, 41–42, 322
Dental calculus, formation of, 58–61
Dental plaque. *See* Plaque
Dental water lines, infection control in, 433–435
Dentilisin, 273, 275
Dentin, 49, 238
Derjaguin-Landau-Vervey-Overbeek theory, 94
Desquamation, as host defense, 207
DIC (disseminated intravascular coagulation), 370
Dimorphic fungi, 334–335
Disinfectants, 442, 445
Disinfection, defined, 436
Disk diffusion test, quantitative, 392–393
Disposal of infected wastes, 440, 443, 445
Disseminated intravascular coagulation (DIC), 370
DNA
bacterial, 15, 16
viral, 296
DNA cloning, 169–172
DNA databases, 74, 183
DNA fingerprinting, in typing of bacterial strains, 195–196
DNA hybridization assays, 80–81, 173, 183–185
DNA polymerase, 170, 173
DNA recovery from clinical samples, 76–77
DNA replication
in bacteria, 15–16
in fungi, 335
in plasmids, 146–151
in viruses, 300–301
DNA transfer. *See* Genetic transfer
DNA viruses, 296, 300–301, 306
Drug interactions, antibiotics and, 402–405
Drug resistance. *See also* Antibiotic resistance
to antifungal agents, 340
to antiviral agents, 330

E

EBV (Epstein-Barr virus), 312, 322
Ecological plaque hypothesis of periodontal disease, 257–258, 293
Efflux pumps, and antibiotic resistance, 414–416, 420
Eikenella corrodens, 275–277
Electrophoresis, 77, 185, 196
Electroporation, 141
Enamel
acquired pellicle of, 207–208
characteristics of, 48–49, 237–238
development of, 238
Endocarditis, infective, 368–370, 375, 402, 403
Endodontic therapy, 349–360
antibacterial agents in, 358–359
bacteriology of, 353–356
culturing and, 356–357
drainage and debridement in, 355, 357–358
focal infection hypothesis, 350, 359
history of, 351–353

Endodontic therapy *(cont.)*
infection sources, 351–353
one-visit therapy, 357
Endoflagella, 153
Endospore production, 14
Endothelium
Porphyromonas gingivalis invasion of, 265–266
Treponema denticola adhesion to, 275
Endotoxin, 9–10. *See also* Lipopolysaccharide
Enterococcus faecalis, in pulpal infections, 355, 359–360
Envelope, viral, 297
Environment, and gene expression, 363–366
Enzymes, fungal, 337
Epidemic population structure, 188–189
Epithelial antibody receptors, 207
Epithelium, mucosal. *See also* Mucosa
antibody-mediated defenses of, 35–36
bacterial colonization of, 107
bacterial internalization by, 61–62, 101–104, 293
Actinobacillus actinomycetemcomitans, 104, 271–272
Porphyromonas gingivalis, 102–104, 265
Prevotella intermedia, 278
growth inhibition of, by *Eikenella corrodens*, 276–277
microbial adhesion to, 51, 96, 104, 275, 278
microbial communication with, 101–104
properties of, 50–51
Epitopes, 33, 34
Epstein-Barr virus (EBV), 312, 322
Erythematous candidiasis, 342–343
Erythromycin, 388, 397, 399
Erythromycin resistance cassette, 141, 144
Eukaryotes, 4–5
Exopolysaccharide, of *Eikenella corrodens*, 276
External defenses, host, 25
Extracellular amorphous material, 270
Extracellular matrix proteins
Actinobacillus actinomycetemcomitans adhesion to, 271
Fusobacterium nucleatum adhesion to, 277
Prevotella intermedia adhesion to, 278
and streptococcal pathogenicity, 363–364
Treponema denticola adhesion to, 274

F

Facemasks, 439–440
Facultative anaerobes, 18–19, 84–85, 118–119
Fas-mediated apoptosis, 43–44
F-ATPase, 111, 112–113
Fc receptors, genetic variability in, 291–292
Fc-binding proteins, 269
Fenton reactions, 118
Fibrillar layer, of gram-positive bacteria, 13
Fibroblasts, *Treponema denticola* adhesion to, 274
Fimbriae
of *Actinobacillus actinomycetemcomitans*, 270
and bacterial adhesion, 92
characteristics of, 13
of *Porphyromonas gingivalis*, 263–265, 267
of *Prevotella intermedia*, 277–278
FISH (fluorescent in situ hybridization), 83–84
Flagella, 13–14, 36, 153
*flg*E mutation, in *Treponema denticola*, 153–156
Fluconazole, 340, 345
Flucytosine, 339–340, 348
Fluorescent in situ hybridization (FISH), 83–84
Fluoride
biofilm physiochemical gradients of, 122–123
and enamel formation, 238
mechanisms of action of, 122–123, 124
and reduction of caries incidence, 235–236
Fluoroquinolone antibiotics, 389, 397, 399, 404, 412–413
Focal infection hypothesis, 350, 359
Fructan, cariogenic bacteria production of, 12–13
Fructosyl transferase, 234, 247–250
ftf gene, of *Streptococcus mutans*, 248–250
FUN genes, 183
Fungal infections, 341–348
aspergillosis, 345–346
blastomycosis, 346–347
candidiasis, 336, 341–345
cryptococcosis, 346
histoplasmosis, 346
mucormycosis, 347
paracoccidiomycosis, 347
treatment of, 338–340
Fungi, 333–348. See also *Candida albicans*; Fungal infections
acid tolerance in, 109
biology of, 333–335
culture and identification of, 338–339
host defenses against, 337–338, 348
pathogenicity of, 5, 335–337
Fusidic acid, 388
Fusion PCR, 144, 162–163
Fusobacterium nucleatum, 277

G

γδ T-cell receptor, 213–214
GB virus C (GBV-C), 300, 304–305
Gel electrophoresis, two-dimensional, 185
GenBank, 74, 183
Gene chips, 251–252
Gene expression
bacterial communicator molecules and, 99–100
regulation of, 98, 99–100, 139, 178–182
in *Streptococcus mutans*, 251
in systemic pathogenicity of commensals, 363–366
Gene expression research
DNA cloning and, 169–172
PCR amplification and, 172–175
reporter genes in, 139, 178–179
in vivo induced antigen technology in, 180–182
Gene function research, 138–141, 175–178
Generalized aggressive periodontitis, 255, 293
Genetic susceptibility, in periodontal disease, 289–292
Genetic transfer, 126–138, 166–167. *See also* Horizontal transmission; Vertical transmission
plasmids and bacteriophage in, 16–17. *See also* Vectors
in population evolution, 189–190
in streptococci, 100, 125, 130–131
in transformable bacteria, 162–163
transposon mutagenesis in, 163–166, 176–178
vectors in. *See* Vectors
Genetic vaccines, 329
Genetics of bacterial populations. *See* Population genetics
Genetics terminology, 125–126
Genome databases, 74, 127, 183

Genome/genome sequencing
bacterial, 15, 74–75, 81–83, 126–127
viral, 296–297, 304–305
Genomics
applications of, 126, 182–183
in caries research, 251–252
Genotype, defined, 125
Gingiva, anatomy of, 50
Gingival crevicular fluid (CGF)
constituents of, 71, 201, 203, 217–218
normal flow of, 71, 201
as oxygen source, 115
in saliva, 64
Gingival sulcus
anatomy of, 50
host defenses in, 283–284
Gingivitis
AIDS and, 321–322
description of, 253, 254
necrotizing ulcerative, 58, 321–322
pathogenesis of, 280–281
plaque microbiota in, 55, 57
of pregnancy, 261
Glasses, 439–440
Glossitis, median rhomboid, 344
Gloves, 438–439
Glucan
in adhesion of bacteria, 94, 234–235
cariogenic bacteria production of, 12–13, 234–235
enzymatic formation of, 247–248
Glucan-binding protein, 245
Glucosyltransferase, 234, 245, 247–250
Glycan hydrolase, 97
Glycolysis, acid tolerance and, 111
Glycopeptide antibiotics, 385
Gram staining, of bacteria, 5
Gramicidin antibiotics, 391
Gram-negative bacteria, 5
bacterial associations of, 97–98
cell wall of, 10
cytoplasmic membrane of, 7, 8
endotoxins of, 9–10. *See also* Lipopolysaccharide
natural transformation in, 132
oral cavity inhabitants, 6
in periodontitis, 246
surface architecture of, 11
vesicle production by, 14
Gram-positive bacteria, 5
cell wall of, 10
cytoplasmic membrane of, 7
lipoteichoic acids of outer envelope, 10–12
oral cavity inhabitants, 6
in periodontitis, 246, 261
surface architecture of, 11
Growth phases of bacteria, 17–19
gtf genes, of *Streptococcus mutans*, 248–250

H

Haemophilus spp., 132, 408
Hairy leukoplakia, 322
Halitosis, 117
Hand, foot, and mouth disease, 309
Handwashing, 437–438
HAV (hepatitis A virus), 309
Hazard, defined, 426
HBV. *See* Hepatitis B virus
HCC (hepatocellular carcinoma), 315, 316, 318
HCV (hepatitis C virus), 300, 317–319
HDV (hepatitis D virus), 317
Heart cross-reacting antibodies, streptococcal, 221–222, 245–246
Heat shock proteins, 370–371
Helper T cells (Th cells), 29
B-lymphocyte interactions, 42
in cell-mediated immunity, 43
in initiation of adaptive immune response, 39, 41–42
in periodontitis, 285, 293
in response to viruses, 323–324
Hemagglutinins, 262–263, 274, 278
Hemin-binding proteins, 274
Hemolytic activity, in virulence, 274, 278
Hepatitis A virus (HAV), 309
Hepatitis B virus (HBV), 300–302, 314–317, 325–326, 444
Hepatitis C virus (HCV), 300, 317–319
Hepatitis D virus (HDV), 317
Hepatocellular carcinoma (HCC), 315, 316, 318
Herpes simplex viruses (HSV), 310–311, 329
Herpes zoster, 311–312
Herpesviruses. *See* Human herpesviruses
HHV. *See* Human herpesviruses
Histatins, salivary, 69, 210
Histidine-rich proteins. *See* Histatins, salivary
Histoplasmosis, 346
HIV. *See* Human immunodeficiency virus
Horizontal transmission, 16–17, 127–130. *See also* Conjugation; Transduction; Transformation
Host adaptations, among bacteria, 190–191, 200
Host defenses, 201–204. *See also* Immune response; Immune system
adherent mucin layer as, 206–207
commensal oral microbiota in, 208, 214
epithelial. *See* Epithelium, mucosal
against fungi, 337–338, 348
in gingival sulcus, 283–284
oxidative defense systems, 119
pellicle as, 207–208
systemic infection and, 366–368
Host factors
in colonization/adhesion of bacteria, 51–53, 90, 91, 96, 101–104
in periodontal disease, 283–284, 289–292, 293. *See also* Periodontal disease, immunopathology
HPV (human papillomaviruses), 313–314
HSV (herpes simplex viruses), 310–311, 329
Human herpesviruses (HHV), 309–313, 325, 329
Human immunodeficiency virus (HIV), 319–322
infection control and, 430–431
postexposure chemoprophylaxis, 445
saliva inactivation of, 70
treatment of, 329–330
Human leukocyte antigens, 38–39, 42, 322–324. *See also* Major histocompatibility complex
Human papillomaviruses (HPV), 313–314
Humoral immunity, 24–27, 209, 214–216, 322. *See also* Antibodies
Hunter, William, 350
Hydrogen peroxide production, 21

Hydrolases, in virulence, 278, 279
Hydroxyl radical, 117–118
Hyphae, fungal, 334

I

Iatrogenic infection, 424
Identification of bacteria, 73, 76–88
  cultivation methods, 73, 84–88
  DNA hybridization assays, 80–81
  DNA recovery from samples, 76–77
  microscopic methods, 83–84
  PCR analysis in, 74, 77–79
  ribosomal 16S cloning and sequence analysis in, 74–75, 81–83
Identification of fungi, 338–339
IL. *See* Interleukin
Immune complexes, 34, 287
Immune response
  to cariogenic bacteria, 242–247. See also *Streptococcus mutans*, immunization against
  to fungi, 337–338
  in periodontitis, 281–282, 284–285. *See also* Periodontal disease, immunopathology
  to viruses, 322–326, 332
Immune system, 23–45
  adaptive immunity, 28–44. *See also* Antibodies
    antigen recognition, 37–39
    initiation of response, 39, 41–42
    lymphoid system and, 28–31
    in oral cavity, 203, 214–219
    T cell interactions, 38–39, 42–43
    viruses and, 323–324
  bacterial evasion of, 282–283
  commensal microbiota regulation by, 218–219
  innate immunity, 23–28, 44, 202–203
    cellular immunity, 23–24
    humoral immunity, 24–27
    interface with adaptive system, 39, 41–42
    on oral surfaces, 204–208
    pathogen recognition by, 27–28
    in saliva, 208–214
    viruses and, 322–323
  mucosal, in transport/translocation of microbes into systemic compartment, 362
  viral evasion of, 325–326
Immunization. *See also* Vaccines
  in caries prevention, 220–224, 228, 242–247
  passive, 223–224, 327
  in periodontitis prevention, 227–228, 289
  against viruses, 326–329
Immunodeficiency. *See* Immunosuppression
Immunoglobulins. *See also* Antibodies
  IgA, 35, 214–215. *See also* Secretory immunoglobulin A
  IgD, 35
  IgE, 35
  IgG, 29, 34–35, 42–43, 203
  IgM, 34, 35, 203
  for passive immunization, 223–224, 327
Immunopathology, defined, 34
Immunopathology of periodontal disease. *See* Periodontal disease, immunopathology
Immunosuppression
  in AIDS, and oral pathology, 321–322
  and fungal infections, 336, 341
Immunosuppression *(cont.)*
  by *Treponema denticola*, 275
Immunosuppressive factor, of *Actinobacillus actinomycetemcomitans*, 268–269, 293
In vivo expression technology (IVET), 180
In vivo induced antigen technology (IVIAT), 180–182
Inactivated vaccines, 327–328
Infection control, 423–446
  biohazardous waste disposal, 440, 443, 445
  checklist for, 440–441
  in dental water lines, 433–435
  emerging infectious diseases and, 430–433
  information sources on, 429
  instrument sterilization, 441–445
  problems in dental practice, 435–437
  risk management in, 423–426
  routes of infection spread, 427–430
  sources of infection, 426–427
  terminology, 435
  universal precautions in, 425, 437–440
Infective endocarditis. *See* Endocarditis, infective
Inflammatory response
  as defense mechanism, 28, 202–203
  mediators of, 28
  Porphyromonas gingivalis and, 266–267
  Prevotella intermedia and, 278–279
  and systemic disease, 372–375
Influenza A virus, 296–297
Innate immunity. *See* Immune system, innate immunity
Insertional mutagenesis, 163–166, 176–178
Insertion-duplication mutagenesis, 176
Instrument sterilization, 441–445
Integration vectors, 159–163
Integrons, in antibiotic resistance, 411–412, 418–419
Interferon, 27, 42, 330–331
Interleukin (IL)
  induction of acute-phase proteins by, 27
  in mucosal defenses, 367
  in periodontitis, 225, 284–285, 287, 293
Intracellular defenses against viruses, 322
Intraoral devices, for caries research, 241
Intravenous drug users, hepatitis B infection in, 316
Isogenic mutants, 139, 145–146
Iteron-regulated replicons, 147
Itraconazole, 345
IVET (in vivo expression technology), 180
IVIAT (in vivo induced antigen technology), 180–182

J

Jenner, Edward, 326
Juvenile periodontitis. *See* Localized aggressive periodontitis

K

Ketoconazole, 345
Knockout of genes, 145–146, 159–160

L

Lactobacillus spp., in cariogenesis, 21, 233, 239, 252
Lactoferrin, 70, 212–213
Lactoferrin-binding proteins, 274
LAP. *See* Localized aggressive periodontitis
Latex hypersensitivity, 439
Lead exposure, and enamel formation, 238
Leeuwenhoek, Antony van, 3

Legionella spp., 434
Leukotoxin, 198, 268, 273, 283, 293
Lincosamide antibiotics, 387
Linezolid, 386, 413–414
Linnaeus, Carl, 4
Lipopolysaccharide (LPS)
  of *Actinobacillus actinomycetemcomitans*, 269
  of *Eikenella corrodens*, 276
  pathogenetic effects of, 9–10, 293, 372
  of *Porphyromonas gingivalis*, 9, 263
  recognition of, by host cells, 367
Lipoteichoic acids, 10–12
Lithium, antibiotic interactions with, 404
Localized aggressive periodontitis (LAP)
  Actinobacillus actinomycetemcomitans and, 193, 198–199, 255, 256, 260
  antibody response in, 255, 285
  neutrophil function in, 281–282
  plaque microbiota in, 58
Localized juvenile periodontitis. *See* Localized aggressive periodontitis
LPS. *See* Lipopolysaccharide
Lymph nodes, 29–31
Lymphocytes. *See also* B lymphocytes; T lymphocytes
  antigen recognition by, 37–39
  function of, 28–29, 44
  in initiation of adaptive immune response, 39, 41–42
  intraepithelial, 213–214, 217
  mucosal, 213–214, 216–217
  recirculation of, 31, 32
  types of, 29
Lymphoid system, 28–31
Lysis of bacteria, for DNA recovery, 76–77
Lysozyme, salivary, 69, 211–212

M

Macrolide antibiotics, 388, 397, 399, 404
Macrophage chemoattractant protein, 367
Macrophages
  in cell-mediated immunity, 43
  in initiation of adaptive immune response, 39, 42, 43
  in innate immunity, 23, 25, 322
Mad cow disease. *See* Transmissible spongiform encephalopathies
Major histocompatibility complex, 38, 292, 322–324. *See also* Human leukocyte antigens
Malodor, oral, 117
Masks, 439–440
Mast cells, in innate immunity, 24, 25
Materia alba, 54
MBC (minimal bacteriocidal concentration), 392, 393
Mechanical forces, and plaque formation, 52
Membranes, bacterial. *See* Cytoplasmic membrane
Metronidazole
  adverse effects of, 397, 404
  resistance to, 401, 413
  spectrum of, 390–391, 397, 399
MIC (minimal inhibitory concentration), 392, 393
Micafungin, 340
Mice
  caries research in, 220, 241–242
  periodontal disease research in, 288–289
Miconazole, 345
Microaerophilic bacteria, 19, 84
Microarrays, for DNA analysis, 80–81, 183–185, 251–252
Microbial physiology, 107–124
  acid tolerance, 52, 109–114, 250
  acid-base cycling in oral cavity, 108–109, 114
  alkali production and tolerance, 109–110, 114–115
  in biofilms, 121–123
  oxygen levels and oxidation-reduction potentials in plaque, 116–117
  oxygen metabolism and oxidative damage, 117–121
  oxygen sources, 115
Microscopy of bacteria, 83–84
Minimal bacteriocidal concentration (MBC), 392, 393
Minimal inhibitory concentration (MIC), 392, 393
Molds, 334
Molecular analysis techniques, 76–83, 138–141. *See also* Polymerase chain reaction; Recombinant DNA technology
  and bacterial classification, 74–75, 83
  DNA hybridization assays, 80–81, 173, 183–185
  DNA recovery from samples, 76–77
  ribosomal 16S cloning and sequence analysis, 74–75, 81–83
Molecular biology, 169–186. *See also* Genetic transfer
  gene expression studies, 169–175
  gene function studies, 138–141, 175–178
  gene regulation studies, 178–182
  genomics, 126, 182–183
  proteomics, 185–186
  transcriptomics, 183–185
Molecular techniques in cariogenesis research, 247–252
Molecular techniques in population genetics research, 195–197
Monobactam antibiotics, 383, 384
Mosaic genes, 127, 129
Motility, in virulence of *Treponema denticola*, 274
Mucins
  and bacterial clearance, 66–67
  complexes formed by, 65
  as host defense, 206–207
  in saliva, 209–210
Mucormycosis, 347
Mucosa. *See also* Epithelium, mucosal
  anatomy of, 50–51
  antibody-mediated defenses of, 35–36
  breaches of, and systemic disease, 361–362
  defense mechanisms of, 35–36, 201–202, 208–209, 214–216, 367
  lymphocytes of, 29, 216–217
  microbial attachment to, 51, 61, 62
Mucosa-associated lymphoid tissues, 29
Mucosal immunization, against streptococci, 222–223
Multilocus enzyme electrophoresis, 196
Multilocus sequence typing, 196–197
Mupirocin, 387
Murein (peptidoglycan), 10, 380–385
Mutacin, 21–22, 101
Mutagenesis
  directed, 163–166, 175–178
  insertional, 163–166, 176–178
Mutants, isogenic, 139, 145–146
Mutation
  and antibiotic resistance, 412–414
  in genetic diversification, 187–188
Mycobacterium tuberculosis, staining of, 5

Mycoplasma spp., staining of, 5

N

Naming of bacteria, 83
NAT2 gene, and periodontitis risk, 292
Natural killer (NK) cells, 24, 322–323
Necrotizing periodontal disease, 255
Necrotizing ulcerative gingivitis, 58, 321–322
Needles, use and disposal of, 440
Neutrophil defects, and periodontitis, 281–282
Neutrophils, and tissue damage in periodontitis, 282, 293
NK (natural killer) cells, 24, 322–323
Nonspecific plaque hypothesis of periodontal disease, 255–256
Nosocomial infection, 424
Nucleic acid synthesis, as antibiotic target, 380, 388–389
Nucleocapsid, 297
Nutrient acquisition
  and bacterial growth, 19
  and coaggregation, 96–98
  from saliva, 70–71
Nutrient levels, in plaque, 121, 123
Nystatin, 344–345

O

Obligate anaerobes, 18, 84
Odontogenic infections, 392–400
  abscesses and cellulitis, 395–396
  antibiotic selection for, 396–400
  bacterial composition of, 351–356
  periapical infections, 394–395
  pericoronitis, 400
Oligonucleotide checkerboard analysis, 80–81
Open reading frames (ORFs), 126, 182–183
Operator, defined, 126
Operon, defined, 126
Operon inducer, defined, 126
Opsonization, 37
Oral cavity
  AIDS-related pathology in, 321–322
  defense mechanisms in, 201–204. *See also* Host defenses; Immune system
  ecology of. *See* Oral ecology
  environment of. *See* Oral environment
  microbacterial niches in, 75
  microbiota of. *See* Oral microbiota
  viruses causing pathology in, 308–314
Oral contraceptives, antibiotic interactions with, 404
Oral ecology, 3, 89–105. *See also* Biofilms; Plaque
  bacterial intercommunication and, 20–22, 99–101, 123
  bacterial–host cell communication and, 101–104
  colonization/adhesion of bacteria in, 91–97
    acquisition of bacteria, 90–91
    bacterial metabolism and, 96–98
    host surface-specific constraints, 96
    mechanisms of, 94–96
    surface structure and molecular promoters of, 91–94
  fundamental concepts in, 20–22
  gene regulation and, 98, 99–100
Oral environment, 47–71
  dental biofilm formation, 61–63
  gingival sulcus, 71
  host and physical parameters in microbial colonization, 51–53
  microbiota in, 53–61. *See also* Oral microbiota
Oral environment *(cont.)*
  saliva in. *See* Saliva
  soft tissues, 50–51
  teeth, 47–50
Oral microbiota. *See also* Bacteria; Fungi; Viruses; *names of specific organisms*
  acquisition of, 90–91, 256, 257, 335–336
  antibiotic resistance in, 401, 416–418. *See also* Antibiotic resistance
  of calculus, 58–61
  commensal organisms. *See* Commensal oral microbiota
  diversity of, 3, 73–74, 192–193
  of mucosa, 61
  normal flora, 5, 22, 333
  pathogenicity of. *See* Pathogenicity; Virulence
  physiology of. *See* Microbial physiology
  of plaque, 53–57, 118–119
  population dynamics in, 193. *See also* Population genetics
  sampling of, 75–76
  significant organisms, 6, 56
Oral mucosa. *See* Mucosa
Oral ulceration, 308–309, 310, 361–362
ORFs (open reading frames), 126, 182–183
Ornidazole, 399
Osteoclasts, activation of, 267
Osteoprotegrin, 286
Outer membrane, of gram-negative bacteria, 7
Outer membrane proteins, 273, 276
Outer membrane vesicles, 14, 264, 269
Oxidation-reduction potentials in plaque, 116–117
Oxidative damage, 18, 52, 117–121
Oxygen
  intraoral levels of, 52, 116–117
  sources of, 115
Oxygen metabolism, 18–19, 117–120
Oxygen radicals. *See* Reactive oxygen species
Oxygen requirements of bacteria, 18–19, 84–86

P

pAMβ1 plasmid, 147
PAMPs. *See* Pathogen-associated molecular patterns
Panmictic population structure, 188
Papillomaviruses. *See* Human papillomaviruses
Paracoccidiomycosis, 347
Parental streptococcal vaccines, adverse effects of, 221
Parenteral routes of infection, 428, 430
Passive immunization
  against *Streptococcus mutans*, 223–224
  against viruses, 327
Pathogen-associated molecular patterns (PAMPs), 202, 205, 367
Pathogenic bacteria, transmission of, 191–192, 427–430
Pathogenicity. *See also* Virulence
  of commensals in systemic infection, 362–366
  of fungi, 335–337
  mechanisms of, 293
  in oral biofilms, 21–22
Pathogenicity islands, 189
PCR. *See* Polymerase chain reaction
Pellicle
  bacterial adhesion and, 51, 53–55, 68–69
  as host defense, 207–208
  salivary components of, 51, 68–69
  and tooth demineralization/remineralization, 64

Pellicle adhesion receptors, 51, 55, 68–69, 92–94
Penicillin antibiotics, 383–384, 396, 398. *See also* Penicillin resistance
Penicillin resistance, 401, 413, 419–420
  history of, 405
  in streptococci, 129, 132
Penicillin-binding proteins, 129, 132, 382–383
Peptidoglycan, 10, 380–385
Perforin-mediated cell death, 43–44
Periapical infections, treatment of, 394–395
Pericoronitis, 400
Periodontal abscesses, 255, 355–356, 359–360, 395–396
Periodontal disease, 253–293. *See also* Gingivitis; Periodontitis
  animal models for, 286–289
  bacterial role in, 255–258. *See also* Periodontal pathogens
  and cardiovascular disease, 266, 359, 372–375
  host genetic factors and, 289–292
  hypotheses of, 255–258
  immunological control of, 224–228, 289
  immunopathology, 279–286
    bacterial virulence and, 225, 282–283
    of gingivitis, 280–281
    immune cells and bone resorption, 285–286
    model for, 283–285
    of periodontal tissue destruction, 281–283, 285–286
  and preterm low-birth-weight babies, 375
  and pulpal infections, 353
  terminology, 255
Periodontal ligament, 50, 281
Periodontal pathogens, 255–258
  A. actinomycetemcomitans. See *Actinobacillus actinomycetemcomitans*
  Capnocytophaga spp., 279
  Eikenella corrodens, 275–277
  Fusobacterium nucleatum, 277
  P. gingivalis. See *Porphyromonas gingivalis*
  Prevotella intermedia, 261, 277–279
  Tannerella forsythia, 261, 279
  T. denticola. See *Treponema denticola*
  virulence traits of, 261–279, 293
  virulence variation between bacterial strains in, 190, 194–195, 197
Periodontal pockets
  amino acid metabolism by bacteria in, 109–110, 114–115
  pH in, 109
  sampling of, 75–76
Periodontitis. *See also* Periodontal disease
  antibiotics for, 394, 400–403
  bacterial species involved in, 256
  chronic, 57–58, 253–254, 260, 292
  description of, 253–254
  generalized aggressive, 254–255, 292–293
  localized aggressive. *See* Localized aggressive periodontitis
  pathogenesis of, 281–282
  plaque microbiota in, 57–58
  viral associations with, 312
Periodontium, 50
Peroxidase, salivary, 70, 119, 212
pH, cytoplasmic, regulation of in acid tolerance, 111
pH, in regulation of gene expression, 363
pH, intraoral
  and cariogenesis, 51–52, 108–109, 111, 235
  fluctuation of, 108–109, 114, 124
Phage. *See* Bacteriophages
Phagocytic cells, in innate immunity, 23–24, 202–203, 322. *See also* Macrophages; Polymorphonuclear cells
Phenotype, defined, 126
Phenotype detection, in cloned DNA studies, 171–172
Pheromone peptides, in competence, 100–101
Phylogenic classification of bacteria. *See* Classification of bacteria
Picornaviridae, 304–305
Pili, 13, 276. *See also* Fimbriae
Plaque, 53–58. *See also* Biofilms
  acid production in, 111–112
  acquired pellicle, in formation of, 53–54
  alkali production in, 109–110, 114–115
  bacterial adhesion, in formation of, 20–21, 54–55, 264–265
  bacterial colonization of, 108
  bacterial interactions in, 20–22
  maturation of, 55–57
  microbiologic composition of, 55–57, 118–119
    in gingivitis, 55, 57
    in necrotizing ulcerative gingivitis, 58
    in periodontitis, 57–58, 59
  oxidation-reduction potentials in, 116–117
  sampling of, 75
Plaque fluid, 218, 219
Plaquelike/nodular candidiasis, 342, 343
Plasma cells, 29, 37, 38
Plasma membrane. *See* Cytoplasmic membrane
Plasmid vectors, 145–159
  essential features of, 146–151
  native, 151–156
  nonnative/broad-host-range, 157–159
  production of, 170–171
Plasmids
  in antibiotic resistance, 135, 136, 405–407, 409, 410–411, 418–419
  categorization of, 146
  characteristics of, 16, 166
  in conjugation, 135
  conjugative vs. mobilizable, 137, 166
  in horizontal genetic transfer, 129
  markers for, 151
  in oral microorganisms, 135–137
  phenotypes associated with, 136–137
  replication mechanisms of, 146–151
  as vectors. *See* Plasmid vectors
Platelet aggregation-associated protein, 364, 369, 371–372
Polymerase chain reaction (PCR)
  applications of, 74, 77–79, 174–175, 196
  fusion PCR, 144, 162–163
  primer design for, 77
  quantitative PCR, 78–79
  technique description, 77–79, 141, 172–174
Polymeric immunoglobulin receptor, 214
Polymorphic fungi, 334–335
Polymorphonuclear cells
  in innate immunity, 23, 25
  and tissue damage in periodontitis, 281–282, 293
Polymyxin antibiotics, 391
Polysaccharide capsule, of *Porphyromonas gingivalis*, 264

Population genetics, 187–200
of commensal bacteria, 191–192, 200
dynamic change in oral species, 193
evolution patterns within species, 187–189
genetic diversity variation among species, 192–193
host adaptations of clones, 190–191
local recombination and, 189–190
strain differentiation, 195–197
strain variations in pathogenicity, 190
virulence variations within species, 194–195, 197
Pores, cytoplasmic membrane, 8, 9
Porins, 9
Porphyromonas endodontalis, 355–356
Porphyromonas gingivalis
in atherosclerotic plaques, 373–375
colonization of, in children, 193, 256, 257
epithelial internalization of, 102–104, 265
in periodontitis, 259, 260
plasmids for research in, 157–159
population genetics of, 193, 194, 197–198
strain variations in virulence, 194
virulence traits of, 259, 260, 262–268, 282–283
Pregnancy gingivitis, 261
Preterm low-birth-weight babies, 375
Prevotella intermedia, 261, 277–279
Primates
caries research in, 221, 240
periodontal disease research in, 286–287
Primer design, for PCR, 77
Prion-associated diseases, 431–433
Prokaryotes, 4–5
Promoter, defined, 126
Prophage, 133–135
Prophylactic use of antibiotics, 394, 402, 403
Proteases
in bacterial virulence, 282–283
of *Porphyromonas gingivalis*, 262, 263, 266
of *Treponema denticola*, 273–274
Protective barriers, 438–440
Protein identification technology, multidimensional, 185–186
Protein synthesis, as antibiotic target, 380, 385–388
Proteins
of cytoplasmic membrane, 7–8
viral, 296, 302
Proteolytic activity, of *Treponema denticola*, 275
Proteomics, 185–186
Pseudomembranous candidiasis, 341–342
Pulp cavity. *See also* Endodontic therapy
anatomy of, 49–50, 349
culturing of, 356–357
infections of, 351–356. *See also* Odontogenic infections
pVA380-1 plasmid, 150, 151–153

Q

Quality assurance, 425
Quantitative PCR (qPCR), 78–79
Quinolone antibiotics, 389
Quorum sensing, 99–100, 130

R

R factor, 407
Random amplified primer DNA fingerprinting, 196
RANK-L proteins, and bone resorption, 286
Rats
caries research in, 220, 241
periodontal disease research in, 289
Reactive oxygen species (ROS), 18, 52, 117–121
Real-time (quantitative) PCR, 78–79
Recombinant DNA technology. *See also* Cloning
in molecular analysis of organisms, 139–143
in vaccine production, 328
Regulons, defined, 126
Replication. *See* DNA replication; RNA viruses, replication of; Theta replication
Replicons, iteron-regulated, 147
Reporter genes, 139, 146, 178–179
Research models
of cariogenesis, 220–221, 239–242
of periodontal disease, 286–289
Restorative procedures, and pulpal infections, 353
Restriction endonucleases, 139–141, 170–171
Restriction fragment length polymorphism, 194, 195
Reverse capture checkerboard analysis, 80–81
Reverse transcriptase, 170
Ribavirin, 331
Ribosomal 16S cloning and sequence analysis, 74–75, 81–83
Ribosomal Database Project, 74
Ribotyping, 195
Rifamycin antibiotics, 388–389, 404
Risk management, 423–426
Risk perception, 424–425, 426
RNA, double-stranded, as intracellular defense trigger, 322
RNA viruses
classification of, 296
replication of, 300, 301
taxonomy of, 307
Rodents
caries research in, 220, 240–242
periodontal disease research in, 287–289
Rolling-circle replication, of plasmids, 146, 147–150
Root canal. *See* Pulp cavity
Root surface caries, 238–239
ROS. *See* Reactive oxygen species

S

Saliva
in adhesion of bacteria, 65
agglutinins in, and bacterial clearance, 66–68
antimicrobial components of, 69–70
bacterial colonization of, 108
bacterial interactions with, 65–71
and bacterial nutrition, 70–71
flow rates of, 53, 208
functional complexes of molecules in, 65–66, 203–204
functions of, 64–66
immunologic defenses in, 69–70, 203–204, 209–214, 366–367
pellicle adhesion receptors, 51, 68–69, 92–94
pellicle formation and, 64–65
production of, 63–64, 208
properties of, 208–209
sampling of, 75
Salivaricin, 101
Salivary glands, 50–51
Sanitization, defined, 436
SARS (severe acute respiratory syndrome), 431
Secretory component, 207, 214

Secretory immunoglobulin A (S-IgA), 214–216
  and acquired specific immunity, 203
  as agglutinin, 67–68
  deficiency of, 214, 220
  duration of antigen response, 242–243, 245
  functions of, 215–216
  fungal infection and, 338
  in innate immunity, 213
  polymeric structure of, 214–215
  production of, 243
Secretory leukocyte protease inhibitor, 211
Segmented viral genomes, 296–297
Severe acute respiratory syndrome (SARS), 431
Sharp instruments, use and disposal of, 440, 443
Sharpey's fibers, 50
Shigella spp., antibiotic resistance in, 405–407
Shingles, 311–312
Shuttle vectors, 151, 156, 166–167, 171–172
S-IgA. *See* Secretory immunoglobulin A
Sigma factor, defined, 126
Site-specific mutagenesis, 163–166, 175–178
S-layer, of bacteria, 14
Slime layer, of *Eikenella corrodens*, 276
Smallpox, 326–327
Southern blot hybridization, 173
SpaP (antigen I/II), 244–245
Specific plaque hypothesis of periodontal disease, 256–257
Spirochetes
  flagella of, 14
  in periodontitis, 261. See also *Treponema denticola*
Spleen, 31
Spongiform encephalopathies, transmissible, 431–433
Spore production, 14
Staining of bacteria, 5
Staphylococcus aureus, antibiotic resistance in, 405, 407, 411, 424
Sterilization
  defined, 435
  of instruments, 441–445
  methods for, 441, 444–445
Stomatitis, 310, 321
Streptococcal vaccines, 220–224, 242–243, 244–247
Streptococci
  adhesins of, 92–93
  antibiotic resistance in, 413, 416–417
  bacteriocin secretion by, 21–22, 101
  competence development in, 100, 130, 131, 132, 166
  genetic transfer in, 100–101, 125, 130–131
  heart cross-reacting antibodies and, 221–222, 245–246
  and infective endocarditis, 368–369, 375
  mucosal immunization against, 222–223
  penicillin resistance in, 129, 132
  salivary amylase binding, 70–71, 93–94
Streptococcus cristatus, 265
Streptococcus mitis, 193, 195
Streptococcus mutans
  adaptations of, 107
  adherence and colonization by, 247–250
  antigens of, 244–245
  bacteriocin production by, 21–22, 101
  colonization of, in children, 193
  gene expression in, 251
  glucan production by, 13
Streptococcus mutans (cont.)
  gtf and *ftf* genes of, 248–250
  immunization against, 220–224, 242–243, 244–247
  natural immunity against, 219–220
  in root cariogenesis, 239
  serotypes and subgroups of, 237
  strain variations in virulence, 195
  stress responses of, 250–251
  sucrose metabolism in, 234, 235
  virulence of, 233–235, 248–249
Streptococcus sobrinus
  in cariogenesis, 233, 252
  DNA transfer via plasmids in, 150, 152–153, 154
  strain variations in virulence, 195
Structural gene, defined, 126
Subgingival antibiotic delivery systems, 401–402
Subgingival caries, 238–239
Sucrose metabolism, in *Streptococcus mutans*, 234, 235
Sugar consumption. *See* Carbohydrate ingestion
Sugar-phosphotransferase system, 19–20
Suicide vectors. *See* Integration vectors
Sulfamethoxazole, 390, 391
Sulfonamide antibiotics, 390, 391, 405–407
Supragingival caries, 237–238
Systemic disease, 361–375. *See also* Atherosclerotic plaques; Endocarditis, infective
  autorecognition and, 371–372
  conditions associated with oral microbes, 368–370, 372–375
  heat shock proteins and, 370–371
  host defenses and, 366–368
  inflammation and, 372–375
  oral to systemic routes for microbes, 361–372
  pathogenicity of commensals in, 362–366

T

T lymphocytes. *See also* Cytotoxic T cells; Helper T cells
  antigen processing by, 38–40
  B cell interactions, 42
  in cell-mediated immunity, 43
  function of, 29, 44–45
  γδ T cells, 213–214
  in initiation of adaptive immune response, 39, 41–42
  mucosal, 216–217
Tannerella forsythia, 261, 279
TaqMan system for qPCR, 78–79
T-cell antigen receptors, 38, 39
Teeth. *See* Tooth
Teichoic acid, 11
Teichuronic acid, 12
Teicoplanin, 385
Temperature, intraoral, 51
Tetracycline antibiotics, 386–387, 398, 401, 417–418, 420
Th cells. *See* Helper T cells
Theta replication, of plasmids, 146, 147–148, 150–151
Thiocyanate, salivary, 70
Thiocyanate-H_2O_2-peroxidase system, 119
Thrombospondin, 211
Thrush, 340–341
Tissue necrosis factor (TNF), 27, 285–286, 367
Tn*916* transposon, 138
Toll-like receptors, 11, 205, 267, 367–368

Tongue
anatomy of, 51
in halitosis production, 117
microbiota of, 61
Tooth, anatomy of, 47–50
Tooth emergence, and bacterial colonization, 90, 91
Tooth plaque. *See* Dental plaque
Transcription, regulation of, 98
Transcriptional fusion, 179
Transcriptomics, 183–185
Transduction, 17, 129, 132–135
Transformation, 16–17, 100, 129, 130–132
Translation, 385–388
Transmissible spongiform encephalopathies, 431–433
Transmission
horizontal vs. vertical, in bacterial genetic transfer, 126–130
of pathogenic bacteria, 191–192, 427–430
Transport proteins, 19
Transporters, efflux, and antibiotic resistance, 414–416, 420
Transposon mutagenesis, 163–166, 176–178
Transposons
in antibiotic resistance, 138, 408–410, 418–419
characteristics of, 137–138, 166
in gene regulation studies, 179–180
in horizontal genetic transfer, 129–130
Trauma, and pulpal infections, 353
Trench mouth, 255
Treponema denticola
adaptations of, 107–108
DNA transfer via plasmids in, 153–156
epithelial interactions of, 104
in periodontitis, 261
in pulpal infections, 354
virulence traits of, 261, 273–275
Treponema lecithinolyticum, 261
Treponema pallidum, 156
Trimethoprim-sulfamethoxazole, 390, 391
Tuberculosis, treatment of, 391
Typing of bacterial strains, 195–196

U

Universal precautions, 425, 437–440
Uptake signal sequence, 132
Urea, ammonia production from, 114–115
Urease, in acid tolerance of bacteria, 114–115, 250, 251

V

Vaccines
adverse effects of, 221, 228, 245–246
for caries prevention, 220–224, 228, 242–247
for periodontitis prevention, 227–228, 289
production methods for, 328–329
for viral diseases, 326–329
Vancomycin, 385, 410–411, 424
Varicella-zostervirus, 311–312
Variola, 326–327
Vectors
integration vectors, 159–163
plasmids as, 145–159
essential features of, 146–151
native, 151–156
nonnative/broad-host-range, 157–159
production of, 170–171
Vectors *(cont.)*
properties of, 145
research uses of, 141, 145–146
Vertical transmission, 126–127, 128
Vesicles, outer membrane, 14, 264, 269
Virion, 297
Virulence. *See also* Pathogenicity
attributes of *Streptococcus mutans*, 233–234
in fungi, 336–337
immune system evasion and, 282–283
of periodontal pathogens, 261–279, 293. *See also names of specific organisms*
variations of, between bacterial strains, 190, 194–195, 197
Viruses, 295–332
antiviral compounds and therapies, 329–331, 332
characteristics and structure of, 295–297, 331
chronic infection establishment by, 325–326
genome of, 296–297, 304–305
hepatitis viruses, 300–302, 309, 314–319, 325–326, 444
human herpesviruses, 309–313, 325, 329
human immunodeficiency virus, 70, 319–322, 329–330, 430–431, 445
human papillomaviruses, 313–314
immune responses to, 322–326, 332
immunization against, 326–329
life cycle of, 297–304, 331
Picornaviridae, 304–305
salivary antiviral factors, 70
S-IgA neutralization of, 216
taxonomy of, 304–308
Von Ebner gland protein, 210

W

Warts, 313–314
Western blot analysis, 172
Whole genomic checkerboard analysis, 80

Y

Yeasts, 334

Z

Ziehl-Neelsen staining, 5